These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 15291687

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
    Jing Y, Kim E, You M, Pikalov A, Tran QV.
    J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
    [Abstract] [Full Text] [Related]

  • 4. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S.
    Cochrane Database Syst Rev; 2013 Nov 18; (11):CD006625. PubMed ID: 24249315
    [Abstract] [Full Text] [Related]

  • 5. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.
    Lublin H, Haug HJ, Koponen H, Sigmundsson T, Kolb SA.
    World J Biol Psychiatry; 2009 Nov 18; 10(4 Pt 3):710-8. PubMed ID: 18803070
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Augmentation of antidepressants with atypical antipsychotics in non-delusional unipolar depressed patients with non-response to antidepressant-monotherapy].
    Erbe S, Gutwinski S, Bschor T.
    Psychiatr Prax; 2012 Mar 18; 39(2):57-63. PubMed ID: 22189902
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Augmentation of antidepressants with atypical antipsychotics: a review of the current literature.
    Philip NS, Carpenter LL, Tyrka AR, Price LH.
    J Psychiatr Pract; 2008 Jan 18; 14(1):34-44. PubMed ID: 18212601
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
    McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK, CATIE Investigators.
    Am J Psychiatry; 2006 Apr 18; 163(4):600-10. PubMed ID: 16585434
    [Abstract] [Full Text] [Related]

  • 13. Second-generation antipsychotics for major depressive disorder and dysthymia.
    Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S.
    Cochrane Database Syst Rev; 2010 Dec 08; (12):CD008121. PubMed ID: 21154393
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M, Erol A, el Mahfoud Kessaci M, Shaheen MO, Sunbol MM, Boland J, Hodge A, O'Halloran RA, Bitter I, IC-SOHO Study Group.
    J Clin Psychiatry; 2004 Mar 08; 65(3):312-21. PubMed ID: 15096069
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Adjunctive risperidone, olanzapine and quetiapine for the treatment of hospitalized patients with bipolar I disorder: a retrospective study.
    Pae CU, Nassir Ghaemi S, Patkar A, Chae JH, Bahk WM, Jun TY, Masand P.
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep 30; 30(7):1322-5. PubMed ID: 16631294
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.